![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/07/05/2909197/0/en/BridgeBio-Pharma-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/06/18/2900308/0/en/BridgeBio-Pharma-Surpasses-Interim-Analysis-Enrollment-Target-and-Receives-U-S-FDA-Rare-Pediatric-Disease-Designation-for-BBP-418-a-Potential-Treatment-for-Limb-girdle-Muscular-Dys.html
https://www.globenewswire.com/news-release/2024/06/10/2895896/0/en/BridgeBio-Pharma-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/06/06/2894570/0/en/BridgeBio-Pharma-to-Participate-in-the-45th-Annual-Goldman-Sachs-Global-Healthcare-Conference.html
https://www.biopharmadive.com/news/bridgebio-infigratinib-achondroplasia-propel-study-results/717914/
https://www.globenewswire.com/news-release/2024/06/04/2892934/0/en/BridgeBio-Announces-Durable-Month-12-and-18-Phase-2-Cohort-5-Results-of-Oral-Infigratinib-in-Achondroplasia-and-First-Participant-Consented-in-ACCEL-for-Hypochondroplasia.html
https://www.globenewswire.com/news-release/2024/06/03/2892563/0/en/BridgeBio-to-Host-Call-on-Month-12-and-18-Phase-2-Cohort-5-Results-of-Oral-Infigratinib-in-Achondroplasia-on-June-4-2024.html
https://endpts.com/bridgebio-touts-additional-attr-cm-drug-data-in-new-analyses-of-phase-3-trial/
https://www.globenewswire.com/news-release/2024/05/29/2890251/0/en/Additional-Data-Showing-Acoramidis-Increases-Serum-Transthyretin-Which-is-Associated-with-Improved-Cardiovascular-Outcomes-Presented-at-ISA-from-BridgeBio-Pharma-s-Phase-3-ATTRibut.html